Scientists create a biological library to prepare for the next pandemic
NCT ID NCT07674550
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This study collects blood, tissue, and other biological samples from adults who have been exposed to, are at risk of, or are diagnosed with an emerging infectious disease. The goal is to create a ready-to-use resource for researchers to better understand how these infections work, identify who is most at risk, and develop better tests and treatments. By planning ahead, scientists hope to respond faster to future outbreaks.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this biobank could speed up research into new diagnostics and treatments for future infectious disease outbreaks.
- What could go wrong
- This is an observational sample collection, not a treatment trial. It may not directly lead to new therapies, and results depend on future research using the samples.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 5,300 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jun 2026
An estimate. Start dates often move.
- Expected to finish
-
Jun 2036
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients presenting with emerging infectious disease
- Ages
-
18 to 99 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients aged 18 years or over * Patients or individuals who have been exposed, are at risk of exposure, or are at risk of complications if exposed, or who are suspected of having, or are diagnosed with, an infectious disease considered to be emerging or at risk of emerging * Patients receiving, or likely to receive, innovative treatments for the infection (new therapeutic molecules, checkpoint inhibitors, cell therapies, etc.) * Patients or individuals receiving, or likely to receive, vaccines or other preventive therapeutic strategies * Pregnant and breastfeeding women may be included. Exclusion Criteria: \- Patients under a legal guardianship arrangement (guardianship, curatorship or court-ordered guardianship)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Emerging infectious diseases and their treatments are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University Hospital Toulouse
Toulouse, 31059, France